RTSN
Retension Pharmaceuticals, Inc.
Price Chart
Latest Quote
$13.52
-0.72 (-5.06%)
Current Price
| Previous Close | $14.24 |
| Open | $14.40 |
| Day High | $14.60 |
| Day Low | $12.70 |
| Volume | 75,338 |
Stock Information
| Shares Outstanding | 8.33M |
| Cash Equivalents | $13.49M |
| Net Income | $-14.24M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $112.64M |
| EPS (TTM) | $-2.61 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $25.60M |
| Income | $-14.24M |
| Book/sh | $-18.48 |
| Cash/sh | $1.62 |
| Employees | 12 |
Financial Ratios
| Quick Ratio | 4.69 |
| Current Ratio | 5.61 |
Returns & Margins
Ownership
| Insider Ownership | 25.70% |
| Institutional Ownership | 23.29% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| P/B | -0.73 |
Analyst Data
| Recommendation | none |
Technical Indicators
| Shares Float | 539K |
Performance History
| Week | -16.44% |
| YTD | +28.40% |
| 10 Years | +28.40% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-10-27 | $13.52 | 75,300 |
| 2026-10-26 | $14.24 | 47,200 |
| 2026-10-23 | $15.25 | 77,900 |
| 2026-10-22 | $15.50 | 121,100 |
| 2026-10-21 | $15.00 | 110,600 |
| 2026-10-20 | $16.18 | 98,300 |
| 2026-10-19 | $16.33 | 267,200 |
| 2026-10-16 | $14.07 | 208,900 |
| 2026-10-15 | $12.21 | 131,000 |
| 2026-10-14 | $11.64 | 77,200 |
| 2026-10-13 | $11.63 | 137,600 |
| 2026-10-12 | $11.32 | 173,900 |
| 2026-10-09 | $10.53 | 789,200 |
About Retension Pharmaceuticals, Inc.
Retension Pharmaceuticals, Inc. operates as a clinical -stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. It offers RTN -001, an oral, small molecule phosphodiesterase -5 inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling. The Company operates as a single operating and reportable segment focused on the development of treatments for hypertension and cardiovascular disease. The company was incorporated in 2023 and is headquartered in Falls Church, Virginia.
đ° Latest News
No news articles available at the moment. Check back later for updates on RTSN.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Revenue | ||
| Total Revenue | $0 | $0 |
| Operating Revenue | $0 | $0 |
| Expenses | ||
| Total Expenses | $6,880,645 | $2,281,298 |
| Net Non Operating Interest Income Expense | $579,363 | $356,514 |
| Operating Expense | $6,880,645 | $2,281,298 |
| General And Administrative Expense | $1,774,536 | $976,369 |
| Other Income Expense | - | $15,073 |
| Income & Earnings | ||
| Net Income From Continuing Operation Net Minority Interest | $-6,301,282 | $-1,909,711 |
| Net Interest Income | $579,363 | $356,514 |
| Interest Income | $579,363 | $356,514 |
| Normalized Income | $-6,301,282 | $-1,924,784 |
| Net Income From Continuing And Discontinued Operation | $-6,301,282 | $-1,909,711 |
| Total Operating Income As Reported | $-6,880,645 | $-2,281,298 |
| Net Income Common Stockholders | $-6,301,282 | $-1,909,711 |
| Net Income | $-6,301,282 | $-1,909,711 |
| Net Income Including Noncontrolling Interests | $-6,301,282 | $-1,909,711 |
| Net Income Continuous Operations | $-6,301,282 | $-1,909,711 |
| Pretax Income | $-6,301,282 | $-1,909,711 |
| Interest Income Non Operating | $579,363 | $356,514 |
| Operating Income | $-6,880,645 | $-2,281,298 |
| Per Share | ||
| Diluted EPS | $-1.38 | $-0.42 |
| Basic EPS | $-1.38 | $-0.42 |
| Other | ||
| Tax Effect Of Unusual Items | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-6,880,645 | $-2,296,371 |
| EBITDA (Bullshit earnings) | $-6,880,645 | $-2,281,298 |
| EBIT | $-6,880,645 | $-2,281,298 |
| Diluted Average Shares | $4,579,273 | $4,581,098 |
| Basic Average Shares | $4,579,273 | $4,581,098 |
| Diluted NI Availto Com Stockholders | $-6,301,282 | $-1,909,711 |
| Research And Development | $5,106,109 | $1,304,929 |
| Selling General And Administration | $1,774,536 | $976,369 |
| Other Gand A | $1,774,536 | $976,369 |
| Total Unusual Items | - | $15,073 |
| Total Unusual Items Excluding Goodwill | - | $15,073 |
| Gain On Sale Of Security | - | $15,073 |
Fetched: 2026-10-26
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Assets | ||
| Net Tangible Assets | $-7,782,923 | $-1,726,679 |
| Total Assets | $21,445,161 | $8,369,959 |
| Total Non Current Assets | $0 | $0 |
| Current Assets | $21,445,161 | $8,369,959 |
| Other Current Assets | $2,544,137 | $184,662 |
| Cash Cash Equivalents And Short Term Investments | $18,901,024 | $8,185,297 |
| Cash And Cash Equivalents | $18,901,024 | $8,185,297 |
| Liabilities | ||
| Total Liabilities Net Minority Interest | $29,228,084 | $10,096,638 |
| Total Non Current Liabilities Net Minority Interest | $28,315,918 | $9,819,670 |
| Current Liabilities | $912,166 | $276,968 |
| Payables And Accrued Expenses | $912,166 | $276,968 |
| Payables | $775,859 | $201,314 |
| Accounts Payable | $775,859 | $194,445 |
| Equity | ||
| Common Stock Equity | $-7,782,923 | $-1,726,679 |
| Total Equity Gross Minority Interest | $-7,782,923 | $-1,726,679 |
| Stockholders Equity | $-7,782,923 | $-1,726,679 |
| Retained Earnings | $-8,315,189 | $-2,013,907 |
| Preferred Securities Outside Stock Equity | $28,315,918 | $9,819,670 |
| Other | ||
| Ordinary Shares Number | $8,331,599 | $8,331,599 |
| Share Issued | $8,331,599 | $8,331,599 |
| Tangible Book Value | $-7,782,923 | $-1,726,679 |
| Invested Capital | $-7,782,923 | $-1,726,679 |
| Working Capital | $20,532,995 | $8,092,991 |
| Total Capitalization | $-7,782,923 | $-1,726,679 |
| Additional Paid In Capital | $532,185 | $287,147 |
| Capital Stock | $81 | $81 |
| Common Stock | $81 | $81 |
| Current Accrued Expenses | $136,307 | $75,654 |
| Dueto Related Parties Current | $0 | $6,869 |
Fetched: 2026-10-26
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Free Cash Flow | ||
| Free Cash Flow | $-7,780,521 | $-1,755,102 |
| Operating Activities | ||
| Operating Cash Flow | $-7,780,521 | $-1,755,102 |
| Cash Flow From Continuing Operating Activities | $-7,780,521 | $-1,755,102 |
| Operating Gains Losses | - | $-15,073 |
| Financing Activities | ||
| Issuance Of Capital Stock | $18,496,248 | $3,614,967 |
| Financing Cash Flow | $18,496,248 | $3,614,967 |
| Cash Flow From Continuing Financing Activities | $18,496,248 | $3,614,967 |
| Net Preferred Stock Issuance | $18,496,248 | $3,614,967 |
| Preferred Stock Issuance | $18,496,248 | $3,614,967 |
| Other | ||
| End Cash Position | $18,901,024 | $8,185,297 |
| Beginning Cash Position | $8,185,297 | $6,325,432 |
| Changes In Cash | $10,715,727 | $1,859,865 |
| Change In Working Capital | $-1,724,277 | $28,948 |
| Change In Other Current Liabilities | $0 | $52,973 |
| Change In Payables And Accrued Expense | $635,198 | $160,637 |
| Change In Accrued Expense | $60,653 | $-9,923 |
| Change In Payable | $574,545 | $170,560 |
| Change In Account Payable | $581,414 | $170,556 |
| Change In Prepaid Assets | $-2,359,475 | $-184,662 |
| Stock Based Compensation | $245,038 | $140,734 |
| Net Income From Continuing Operations | $-6,301,282 | $-1,909,711 |
| Gain Loss On Investment Securities | - | $-15,073 |
Fetched: 2026-10-26